Skip to main content
SpringerLink
Log in

Cancer Risks and Screening with Current and Emerging Drug Therapies in Inflammatory Bowel Diseases

  • Chapter
  • First Online:
Cancer Screening in Inflammatory Bowel Disease

  • 370 Accesses

Abstract

Patients with inflammatory bowel disease have been found to be at higher risk for developing certain malignancies compared to the general population. The increased risk has been linked to their underlying IBD as well as exposure to certain classes of immunosuppressant treatments. Over the past few decades, multiple studies have been performed to assess the risk for lymphoma, melanoma, and nonmelanoma skin cancers in patients who have been treated with thiopurines and anti-tumor necrosis factor alpha (anti-TNF). There is minimal data available at this time to link increased risk of malignancies to exposure to anti-integrins (such as vedolizumab), anti-IL 12/23 agents (such as ustekinumab), or Janus kinase inhibitors (such as tofacitinib) in IBD patients.

Helen Lee and Yecheskel Schneider contributed equally to the work and are co-first authors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jacobson CA, Longo DL. Non-Hodgkin’s lymphoma. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s principles of internal medicine, 20e. New York: McGraw-Hill. http://accessmedicine.mhmedical.com/content.aspx?bookid=2129&sectionid=192018038. Accessed 16 July 2018.

  2. Jacobson CA, Longo DL. Hodgkin’s lymphoma. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s principles of internal medicine, 20e. New York: McGraw-Hill. http://accessmedicine.mhmedical.com/content.aspx?bookid=2129&sectionid=192018130. Accessed 16 July 2018.

  3. The National Cancer Institute: Surveillance, Epidemiology, and End Results Program (2018). https://seer.cancer.gov/. Accessed 23 July 2018.

  4. American Cancer Society: Lymphoma (2018). https://www.cancer.org/cancer/lymphoma.html. Accessed 23 July 2018.

  5. Bargen JA. Chronic ulcerative colitis associated with malignant disease. Arch Surg. 1928;17:561–76.

    Article  Google Scholar 

  6. Greenstein AJ, Gennuso R, Sachar DB, Heimann T, Smith H, Janowitz HD, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer. 1985;56:2914–21. https://doi.org/10.1002/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J.

    Article  CAS  PubMed  Google Scholar 

  7. Masel S, Hanauer S. Increased association of lymphoma and inflammatory bowel disease. Gastroenterology. 2000;118:A119.

    Article  Google Scholar 

  8. Farrell RJ, Ang Y, Kileen P, O’Briain DS, Kelleher D, Keeling PWN, et al. Increased incidence of non-Hodgkin’s lymphomas in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67:2015–9.

    Article  CAS  PubMed  Google Scholar 

  10. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostom O, Ahlbom A, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology. 1994;107:1675–9.

    Article  CAS  PubMed  Google Scholar 

  11. Karlen P, Lofberg R, Brostrom O, Leijonmarck CE, Helllers G, Persson PG. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999;94:1047–52.

    Article  CAS  PubMed  Google Scholar 

  12. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2(2):1088–95.

    Article  PubMed  Google Scholar 

  13. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County. Denmark Aliment Pharmacrol Ther. 2004;19:287–93.

    Article  CAS  Google Scholar 

  14. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.

    Article  CAS  PubMed  Google Scholar 

  15. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427–36.

    Article  CAS  PubMed  Google Scholar 

  16. Vos ACW, Bakkal N, Minnee RC, Casparie MK, de Jong DJ, Dijkstra G, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis. 2011;17:1837–45.

    Article  CAS  PubMed  Google Scholar 

  17. Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95(9):2308–12.

    Article  PubMed  Google Scholar 

  18. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080–7.

    Article  CAS  PubMed  Google Scholar 

  19. Askling J, Brandt L, Lapidus A, Karlen P, Bjorkholm M, Lofberg R, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854–62.

    Article  CAS  PubMed  Google Scholar 

  21. Palli D, Trallori G, Bagnoli S, Saieva C, Tarantino O, Ceroti M, et al. Hodgkin’s disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000;119:647–53.

    Article  CAS  PubMed  Google Scholar 

  22. Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology. 2001;121:1240–1.

    Article  Google Scholar 

  23. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or the treatment? Inflamm Bowel Dis. 2007;13:1299–307.

    Article  PubMed  Google Scholar 

  24. Bewtra M. Lymphoma in inflammatory bowel disease and treatment decisions. Am J Gastroenterol. 2012;107:964–70.

    Article  PubMed  Google Scholar 

  25. Subramaniam K, D’Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol. 2013;28(1):24–30.

    Article  CAS  PubMed  Google Scholar 

  26. American Cancer Society. Cancer facts and figures (2018). https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed 23 July 2018.

  27. American Cancer Society. Melanoma skin cancer (2018). https://www.cancer.org/cancer/melanoma-skin-cancer.html. Accessed 23 July 2018.

  28. Curti BD, Leachman S, Urba WJ. Cancer of the skin. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s principles of internal medicine, 20e. New York: McGraw-Hill. http://accessmedicine.mhmedical.com/content.aspx?bookid=2129&sectionid=192015390. Accessed 16 July 2018.

  29. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081–6.

    Article  PubMed  Google Scholar 

  30. World Health Organization. Skin cancers. http://www.who.int/uv/faq/skincancer/en/index2.html. Accessed 23 July 2018.

  31. Skin Cancer Foundation. Skin cancer facts & statistics. https://www.skincancer.org/skin-cancer-information/skin-cancer-facts. Accessed 23 July 2018.

  32. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136(12):1524–30.

    Article  CAS  PubMed  Google Scholar 

  33. Singh S, Nagpal SJS, Murad MH, Yadav S, Kane SV, Pardi DS, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:210–8.

    Article  PubMed  Google Scholar 

  34. Nissen LHC, Pierik M, Derikx LAAP, de Jong E, Kievit W, van den Heuvel TR, et al. Risk factors and clinical outcomes in patients with IBD with melanoma. Inflamm Bowel Dis. 2017;23:2018–26.

    Article  PubMed  Google Scholar 

  35. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventative care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–58.

    Article  PubMed  Google Scholar 

  36. Mellemkjaer L, Olsen JH, Frisch M, Johansen C, Gridley G, McLaughlin JK. Cancer in patients with ulcerative colitis. Ing J Cancer. 1995;60:330–3.

    Article  CAS  Google Scholar 

  37. Long MD, Herfarth HH, Pipkin C, Porter CQ, Sandler RS, Kappelman M. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8(3):268–74.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141:1612–20.

    Article  PubMed  Google Scholar 

  39. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(3):390–9.

    Article  PubMed  Google Scholar 

  40. Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–15.

    Article  CAS  PubMed  Google Scholar 

  42. Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13(5):847–58.

    Article  CAS  PubMed  Google Scholar 

  43. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ registry. Am J Gastroenterol. 2014;109:212–23.

    Article  CAS  PubMed  Google Scholar 

  44. Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanstrom H, Capsersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–13.

    Article  PubMed  Google Scholar 

  45. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106(12):2146–53.

    Article  CAS  PubMed  Google Scholar 

  46. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Farrell RJ, Ang Y, Kileen P, O’Briain DS, Kelleher D, Keeling PW, et al. Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831–41.

    Article  PubMed  Google Scholar 

  49. Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36.

    Article  CAS  PubMed  Google Scholar 

  50. Lichtenstein GR, Loftus EV, Bloom S, Lawendy N, Friedman GS, Zhang H, et al. Tofacitinib, an Oral Janus kinase inhibitor, in the treatment of ulcerative colitis: open-label, Long-term extension study. Poster presentation Digestive Diseases Week. October 2017.

    Google Scholar 

  51. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60.

    Article  CAS  PubMed  Google Scholar 

  52. Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–21.

    Article  CAS  PubMed  Google Scholar 

  53. Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3–15.

    Article  CAS  PubMed  Google Scholar 

  54. McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the food and drug administration adverse event reporting system. J Gastrointestin Liv Dis. 2014;23(3):267–71.

    Google Scholar 

  55. Yadav S, Singh S, Harmsen WS, Varayil JE, Tremaine WJ, Loftus EV Jr. Effects of medications on risk of cancer in patients with inflammatory bowel diseases: a population-based cohort study from Olmsted County. Minnesota Mayo Clin Proc. 2015;90(6):738–46.

    Article  CAS  PubMed  Google Scholar 

  56. Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146(4):941–9.

    Article  CAS  PubMed  Google Scholar 

  57. Cohn HM, Dave M, Loftus EV Jr. Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(8):1301–15.

    Article  PubMed  Google Scholar 

  58. Peyrin-Biroulet L, Chevaux JB, Bouvier AM, Carrat F, Beaugerie L. Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. Am J Gastroenterol. 2012;107:1443–4.

    Article  CAS  PubMed  Google Scholar 

  59. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014;109:163–9.

    Article  CAS  PubMed  Google Scholar 

  60. Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench Z, Zhang J, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152(2):164–72.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Hagen JW, Pugliano-Mauro MA. Nonmelanoma skin cancer risk in patients with inflammatory bowel disease undergoing thiopurine therapy: a systematic review of the literature. Dermatol Surg. 2018;44(4):469–80.

    Article  CAS  PubMed  Google Scholar 

  62. Abbas AM, Almuktar RM, Loftus EV Jr, Lichenstein GR, Khan N. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol. 2014;109(11):1781–93.

    Article  CAS  PubMed  Google Scholar 

  63. Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21:1847–53.

    Article  PubMed  Google Scholar 

  64. Long MD, Kappelman MD, Pipkin CA. Non-melanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis. 2011;17(6):1423–7.

    Article  PubMed  Google Scholar 

  65. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621–8.

    Article  CAS  PubMed  Google Scholar 

  66. Anderson AJ, Ferris LK, Binion DG, Smith KJ. Cost-effectiveness of melanoma screening in inflammatory bowel disease. Dig Dis Sci. 2018;63(10):2564–72.

    Article  PubMed  Google Scholar 

  67. Anderson AJ, Ferris LK, Click B, Ramos-Rivera C, Koutroubakis IE, Hashash JG, et al. Low rates of dermatologic care and skin cancer screening among inflammatory bowel disease patients. Dig Dis Sci. 2018;63(10):2729–39.

    Article  PubMed  Google Scholar 

  68. Kimmel JN, Taft TH, Keefer L. Inflammatory bowel disease and skin cancer: an assessment of patient risk factors, knowledge and skin practices. J Skin Cancer. 2016;2016:4632037.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

      Helen Lee, Yecheskel Schneider & Gary R. Lichtenstein

    2. University of Pennsylvania School of Medicine, Philadelphia, PA, USA

      Helen Lee, Yecheskel Schneider & Gary R. Lichtenstein

    3. Center for Inflammatory Bowel Diseases, The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA

      Gary R. Lichtenstein

    4. Gastroenterology Division, Department of Internal Medicine, Perelman Center for Advanced Medicine, Philadelphia, PA, USA

      Gary R. Lichtenstein

    Authors
    1. Helen Lee
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Yecheskel Schneider
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Gary R. Lichtenstein
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Gary R. Lichtenstein .

    Editor information

    Editors and Affiliations

    1. Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA

      Joseph D. Feuerstein

    2. Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA

      Adam S. Cheifetz

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2019 Springer Nature Switzerland AG

    About this chapter

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this chapter

    Lee, H., Schneider, Y., Lichtenstein, G.R. (2019). Cancer Risks and Screening with Current and Emerging Drug Therapies in Inflammatory Bowel Diseases. In: Feuerstein, J., Cheifetz, A. (eds) Cancer Screening in Inflammatory Bowel Disease . Springer, Cham. https://doi.org/10.1007/978-3-030-15301-4_8

    Download citation

    • DOI: https://doi.org/10.1007/978-3-030-15301-4_8

    • Published:

    • Publisher Name: Springer, Cham

    • Print ISBN: 978-3-030-15300-7

    • Online ISBN: 978-3-030-15301-4

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation